NCT07011654View on ClinicalTrials.gov

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

September 19, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2030

Conditions

Metastatic Triple-Negative Breast Cancer

Interventions

DRUG

Sacituzumab govitecan

Given by IV

DRUG

Naxitamab

Given by IV

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Y-mAbs Therapeutics

All Listed Sponsors

collaborator

Y-mAbs Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT07011654 - Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) | Biotech Hunter | Biotech Hunter